• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Emergence of SARS-CoV-2 omicron variant JN.1 in Tamil Nadu, India - Clinical characteristics and novel mutations

tetano

Editor, Senior Moderator
Sci Rep


. 2024 Jul 30;14(1):17476.
doi: 10.1038/s41598-024-68678-z. Emergence of SARS-CoV-2 omicron variant JN.1 in Tamil Nadu, India - Clinical characteristics and novel mutations

Sivaprakasam T Selvavinayagam[SUP] #[/SUP][SUP] 1 [/SUP], Sathish Sankar[SUP] #[/SUP][SUP] 2 [/SUP], Yean K Yong[SUP] #[/SUP][SUP] 3 4 [/SUP], Amudhan Murugesan[SUP] 5 [/SUP], Suvaiyarasan Suvaithenamudhan[SUP] #[/SUP][SUP] 6 [/SUP], Kannan Hemashree[SUP] 1 [/SUP], Manivannan Rajeshkumar[SUP] 1 [/SUP], Anandhazhvar Kumaresan[SUP] 1 [/SUP], Ramendra P Pandey[SUP] 7 [/SUP], Saravanan Shanmugam[SUP] 8 [/SUP], Parthiban Arthydevi[SUP] 1 [/SUP], Masilamani Senthil Kumar[SUP] 1 [/SUP], Natarajan Gopalan[SUP] 9 [/SUP], Meganathan Kannan[SUP] 10 [/SUP], Narayanaiah Cheedarla[SUP] 11 [/SUP], Hong Y Tan[SUP] 12 [/SUP], Ying Zhang[SUP] 4 13 [/SUP], Marie Larsson[SUP] 14 [/SUP], Pachamuthu Balakrishnan[SUP] 15 [/SUP], Vijayakumar Velu[SUP] 11 [/SUP], Siddappa N Byrareddy[SUP] 16 [/SUP], Esaki M Shankar[SUP] 17 [/SUP], Sivadoss Raju[SUP] 18 [/SUP]



Affiliations
Abstract

In December 2023, we observed a notable shift in the COVID-19 landscape, when JN.1 omicron emerged as the predominant SARS-CoV-2 variant with a 95% incidence. We characterized the clinical profile, and genetic changes in JN.1, an emerging SARS-CoV-2 variant of interest. Whole genome sequencing was performed on SARS-CoV-2 positive clinical specimens, followed by sequence analysis. Mutations within the spike protein sequences were analysed and compared with the previously reported lineages and sub-lineages, to identify the potential impact of the unique mutations on protein structure and possible alterations in the functionality. Several unique and dynamic mutations were identified herein. Molecular docking analysis showed changes in the binding affinity, and key interacting residues of wild-type and mutated structures with key host cell receptors of SARS-CoV-2 entry viz., ACE2, CD147, CD209L and AXL. Our data provides key insights on the emergence of newer variants and highlights the necessity for robust and sustained global genomic surveillance of SARS-CoV-2.

Keywords: JN.1 variant; Mutation; Omicron variant; SARS-CoV-2; Spike protein; Whole genome sequencing.

 
Back
Top Bottom